Satellos Changes Primary Endpoint to MRI-Measured Fat Fraction in Phase 2 Duchenne Trial After FDA Feedback

• Satellos Bioscience selected MRI-measured muscle fat fraction to replace strength testing as the primary endpoint in its Phase 2 BASECAMP trial.
• The change follows FDA feedback; supportive results could support a potential accelerated approval pathway for forazapadin.
• BASECAMP is evaluating the investigational oral drug in boys ages 7 to 9 with Duchenne muscular dystrophy.
• Topline results from the 12-week placebo-controlled period are expected in the first quarter of 2027.
• Previously reported TRAILHEAD results in adults showed improved muscle composition, with safety and tolerability consistent with earlier findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060700PRIMZONEFULLFEED9871771) on November 06, 2026, and is solely responsible for the information contained therein.